Pacific Biosciences of California, INC

Pacific Biosciences of California, Inc. announced the immediate resignation of board member Christopher M. Smith.

Pacific Biosciences stockholders approved an amendment to the 2020 Equity Incentive Plan and re-elected four Class III directors at the 2026 Annual Meeting.

Pacific Biosciences of California, Inc. announced the appointment of Dr. Christopher Gibson, co-founder of Recursion, to its Board of Directors, enhancing its focus on AI and data-driven discovery.

PacBio announced its fourth quarter and full year 2025 financial results, showing revenue growth and improved non-GAAP net loss, alongside strategic advancements in long-read sequencing.

Pacific Biosciences announced an interim reassignment of responsibilities between its Chief Operating Officer and President & CEO, effective January 28, 2026.

PacBio completed the strategic sale of its short-read DNA sequencing technology assets to Illumina for $48.1 million in net cash, sharpening its focus on long-read sequencing.

Pacific Biosciences reports flat Q1 2026 revenue of $37.2 million and a narrowed net loss of $8.3 million following strategic restructuring.

Pacific Biosciences reports a slight revenue increase to $115.4 million for the nine months ended September 30, 2025, but operating loss significantly widens to $512.7 million due to substantial restructuring charges and asset impairments.

Pacific Biosciences of California, Inc. reported a significant net loss in Q2 2025, driven by substantial non-cash restructuring charges, despite modest revenue growth and strategic progress in its HiFi sequencing platforms.

Pacific Biosciences' Q1 2025 results reveal a revenue decrease and substantial operating losses as the company undergoes a strategic restructuring.

Pacific Biosciences' Q3 2024 results show a decrease in revenue and a significant goodwill impairment charge, alongside ongoing restructuring efforts.

Pacific Biosciences' Q2 2024 results reveal a decrease in revenue and a significant goodwill impairment charge, leading to a substantial net loss, while the company initiates restructuring efforts to reduce operating expenses.

Pacific Biosciences of California, Inc. reports a strategic shift towards HiFi sequencing, an asset sale, and a net loss of $546.4 million for fiscal year 2025, alongside a decrease in cash and investments.

Pacific Biosciences' 2024 results reveal a revenue decline offset by strategic initiatives and product launches, setting the stage for a transformative 2025.

Pacific Biosciences' 2023 financial results show significant revenue growth due to the commercial release of its Revio and Onso sequencing platforms, though gross margins declined.

Pacific Biosciences director Marshall Mohr was granted an option to purchase 223,492 shares of common stock.

Director Christopher Gibson was granted 74,497 stock options in Pacific Biosciences of California, Inc. as part of standard compensation.

Director Christopher M. Smith was granted 223,492 stock options in Pacific Biosciences of California, Inc. on June 3, 2026.

Director Hannah Valantine was granted 223,492 stock options in Pacific Biosciences of California, Inc. on June 3, 2026.

Pacific Biosciences director Randall S. Livingston was granted 223,492 stock options as part of standard equity compensation.

Pacific Biosciences of California director William W. Ericson was granted 223,492 stock options as part of his compensation.

Pacific Biosciences of California, Inc. has filed its 2026 Proxy Statement, outlining proposals for the upcoming Annual Meeting, including director elections, executive compensation, and an amendment to the 2020 Equity Incentive Plan.

Pacific Biosciences has filed a definitive proxy statement with the SEC.

Pacific Biosciences has filed a definitive proxy statement with the SEC.

Pacific Biosciences is asking stockholders to approve an amendment to its 2020 Equity Incentive Plan to increase the number of shares reserved for issuance.

Pacific Biosciences of California, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Pacific Biosciences of California, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Pacific Biosciences of California Inc following an internal realignment.

ARK Investment Management LLC and Catherine D. Wood have jointly filed an Amendment No. 6 on Schedule 13G, disclosing a combined beneficial ownership of 12.34% in Pacific Biosciences of California, Inc.

Madrone Capital Partners and related entities, including Gregory Penner, filed an amended Schedule 13G disclosing their beneficial ownership in Pacific Biosciences of California, Inc.

ARK Investment Management LLC and Catherine D. Wood have disclosed a 10.30% beneficial ownership stake in Pacific Biosciences of California, Inc.

Madrone Capital Partners and related entities disclose increased beneficial ownership in Pacific Biosciences of California, Inc., reaching 6.8% of common stock.

Edmond de Rothschild Asset Management entities and Edmond de Rothschild Fund have disclosed beneficial ownership of up to 4.5% of Pacific Biosciences of California, Inc. common stock as of June 30, 2025.